Cargando…

Pharmacological Potential of Cilostazol for Alzheimer’s Disease

Alzheimer’s disease (AD), a slow progressive form of dementia, is clinically characterized by cognitive dysfunction and memory impairment and neuropathologically characterized by the accumulation of extracellular plaques containing amyloid β-protein (Aβ) and neurofibrillary tangles containing tau in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ono, Kenjiro, Tsuji, Mayumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540873/ https://www.ncbi.nlm.nih.gov/pubmed/31191308 http://dx.doi.org/10.3389/fphar.2019.00559

Ejemplares similares

Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease
por: Ono, Kenjiro, et al.
Publicado: (2020)

Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
por: Oguchi, Tatsunori, et al.
Publicado: (2017)

Advances in Alzheimer’s disease’s pharmacological treatment
por: Conti Filho, Carlos Elias, et al.
Publicado: (2023)

Cilostazol Ameliorates Peripheral Neuropathic Pain in Streptozotocin-Induced Type I Diabetic Rats
por: Cheng, Kuang-I., et al.
Publicado: (2022)

Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease
por: Cuello, A. Claudio, et al.
Publicado: (2019)

Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case–Crossover Study
por: Wu, Cho-Kai, et al.
Publicado: (2019)

Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task
por: Cassano, Tommaso, et al.
Publicado: (2019)

Pharmacological effects of natural medicine ginsenosides against Alzheimer’s disease
por: Shi, Zhikun, et al.
Publicado: (2022)

Pharmacological models in Alzheimer's disease research
por: Gilles, Christian, et al.
Publicado: (2000)

Effect of Baicalein on the Pharmacokinetics of Cilostazol and Its Two Metabolites in Rat Plasma Using UPLC-MS/MS Method
por: Weng, Qinghua, et al.
Publicado: (2022)

Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH
por: Park, Joon Beom, et al.
Publicado: (2023)

Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer’s Disease: A Systematic Review
por: Theleritis, Christos G., et al.
Publicado: (2019)

Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimer’s Disease
por: Luo, Yunxia, et al.
Publicado: (2020)

Integrated comparative metabolomics and network pharmacology approach to uncover the key active ingredients of Polygonati rhizoma and their therapeutic potential for the treatment of Alzheimer’s disease
por: Wang, Fu, et al.
Publicado: (2022)

Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease
por: Sharma, Abha, et al.
Publicado: (2018)

Network Pharmacology-Based Analysis of Xiao-Xu-Ming Decoction on the Treatment of Alzheimer’s Disease
por: Shen, Yanjia, et al.
Publicado: (2020)

Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease
por: McKee, Chloe G., et al.
Publicado: (2023)

Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease
por: Luo, Yunxia, et al.
Publicado: (2023)

Neuroprotective Potential and Underlying Pharmacological Mechanism of Carvacrol for Alzheimer’s and Parkinson’s Diseases
por: Javed, Hayate, et al.
Publicado: (2023)

Pharmacodynamics, Network Pharmacology, and Pharmacokinetics of Chinese Medicine Formula 9002A in the Treatment of Alzheimer’s Disease
por: Tang, Chunlan, et al.
Publicado: (2022)

Network pharmacology‒based analysis of marine cyanobacteria derived bioactive compounds for application to Alzheimer’s disease
por: Xie, Rui, et al.
Publicado: (2023)

Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice
por: Yanai, Shuichi, et al.
Publicado: (2022)

Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer’s Disease: A Bayesian Network Meta-Analysis
por: Zhang, Tingting, et al.
Publicado: (2020)

A Tau Pathogenesis-Based Network Pharmacology Approach for Exploring the Protections of Chuanxiong Rhizoma in Alzheimer’s Disease
por: Zeng, Peng, et al.
Publicado: (2022)

Trilateral association of autophagy, mTOR and Alzheimer’s disease: Potential pathway in the development for Alzheimer’s disease therapy
por: Subramanian, Arunkumar, et al.
Publicado: (2022)

Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study
por: Tai, Shu-Yu, et al.
Publicado: (2017)

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease
por: Martins, Gabriela L., et al.
Publicado: (2023)

Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials
por: Xu Lou, Inmaculada, et al.
Publicado: (2023)

Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
por: Cenini, Giovanna, et al.
Publicado: (2019)

Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease
por: Behl, Tapan, et al.
Publicado: (2022)

Metabolic changes in the plasma of mild Alzheimer’s disease patients treated with Hachimijiogan
por: Kainuma, Mosaburo, et al.
Publicado: (2023)

An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease
por: Kainuma, Mosaburo, et al.
Publicado: (2022)

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
por: Hampel, Harald, et al.
Publicado: (2019)

Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota
por: Yang, Shengjie, et al.
Publicado: (2021)

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
por: Beggiato, Sarah, et al.
Publicado: (2019)

Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease
por: Shal, Bushra, et al.
Publicado: (2018)

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease
por: Rahman, Md. Habibur, et al.
Publicado: (2020)

R-carvedilol, a potential new therapy for Alzheimer’s disease
por: Yao, Jinjing, et al.
Publicado: (2022)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
por: Boyarko, Ben, et al.
Publicado: (2023)

Computational and Pharmacological Evaluation of Carveol for Antidiabetic Potential
por: Ahmed, Muhammad Shabir, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lj4bpd3fsmohmn3kehchref1rv